Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Clin Breast Cancer ; 23(6): 576-590, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37286435

RESUMO

BACKGROUND: Current anticancer treatments for breast cancer (BC) may cause cardiotoxicity. This study aimed to investigate the effectiveness of aerobic exercise in mitigating cardiotoxicity caused by BC therapy. MATERIALS AND METHODS: PubMed, Embase, Cochrane Library, Web of Science, and the Physiotherapy Evidence Database were searched until February 7, 2023. Clinical trials investigating the effectiveness of exercise training, including aerobic exercise, in BC patients receiving treatments that could cause cardiotoxicity were eligible. Outcome measures included cardiorespiratory fitness (CRF) (peak oxygen consumption, VO2peak), left ventricular ejection fraction, and peak oxygen pulse. Intergroup differences were determined by standard mean differences (SMD) and 95% confidence intervals (CIs). Trial sequential analysis (TSA) was utilized to ensure whether the current evidence was conclusive. RESULTS: Sixteen trials involving 876 participants were included. Aerobic exercise significantly improved CRF measured by VO2peak in mL/kg/min (SMD 1.79, 95% CI 0.99-2.59) when compared to usual care. This result was confirmed through TSA. Subgroup analyses revealed that aerobic exercise given during BC therapy significantly improved VO2peak (SMD 1.84, 95% CI 0.74-2.94). Exercise prescriptions at a frequency of up to 3 times per week, an intensity of moderate to vigorous, and a >30-minute session length also improved VO2peak. CONCLUSION: Aerobic exercise is effective in improving CRF when compared to usual care. Exercise performed up to 3 times per week, at a moderate-to-vigorous intensity, and having a session length >30 minutes is considered effective. Future high-quality research is needed to determine the effectiveness of exercise intervention in preventing cardiotoxicity caused by BC therapy.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Neoplasias da Mama/terapia , Cardiotoxicidade/etiologia , Cardiotoxicidade/prevenção & controle , Estudos de Viabilidade , Volume Sistólico , Função Ventricular Esquerda , Exercício Físico
2.
Medicina (Kaunas) ; 58(8)2022 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-36013530

RESUMO

Guillain-Barré syndrome (GBS) often develops after a respiratory or gastrointestinal infection. A few cases have been reported on GBS following elective spinal surgery not preceded by an infectious disease. In patients with underlying upper motor neuron disease such as a spinal cord injury, concurrent development of lower motor neuron diseases, such as GBS, could be overlooked. Here, we present an uncommon case of an 87-year-old man with GBS that had developed after an operation for a traumatic cervical spinal cord injury. After surgery, he showed weakness over all four limbs with paresthesia, but he was able to hold a standing position with minimal assistance. Unfortunately, his muscle strength over his four limbs gradually weakened from two to four weeks later, and he became almost completely paralyzed. Cerebrospinal fluid (CSF) studies revealed albuminocytologic dissociation. A nerve conduction study (NCS) indicated an acute axonal polyneuropathy superimposed on chronic sensorimotor polyneuropathy. Thus, the patient was diagnosed with GBS. However, the patient's family declined immune-modulatory therapy due to personal reasons. The patient progressed into respiratory failure and remained ventilator-dependent before his death three years later. This case highlights the importance of taking GBS into account when postoperative weakness occurs in patients with spinal cord injury, and a worse prognosis if GBS is left untreated.


Assuntos
Medula Cervical , Síndrome de Guillain-Barré , Polineuropatias , Insuficiência Respiratória , Traumatismos da Medula Espinal , Idoso de 80 Anos ou mais , Medula Cervical/cirurgia , Síndrome de Guillain-Barré/etiologia , Humanos , Masculino , Polineuropatias/complicações , Insuficiência Respiratória/etiologia , Traumatismos da Medula Espinal/complicações , Traumatismos da Medula Espinal/cirurgia
3.
Int J Mol Sci ; 22(23)2021 Nov 23.
Artigo em Inglês | MEDLINE | ID: mdl-34884429

RESUMO

As a source of growth factors for expediting wound healing and tissue regeneration, plasma-rich plasma (PRP) has been extensively applied in diverse fields including orthopaedics, ophthalmology, oral and maxillofacial surgery, dentistry, and gynaecology. However, the function of PRP in metabolic regulations remains enigmatic. A standardized method was devised herein to enrich growth factors and to lyophilize it as enhanced PRP (ePRP) powder, which could become ubiquitously available without mechanical centrifugation in clinical practice. To identify metabolic reprogramming in human dermal fibroblasts under ePRP treatment, putative metabolic targets were identified by transcriptome profiling and validated for their metabolic effects and mechanism. ePRP does not only promote wound healing but re-aligns energy metabolism by shifting to glycolysis through stimulation of glycolytic enzyme activity in fibroblasts. On the contrary, oxygen consumption rates and several mitochondrial respiration activities were attenuated in ePRP-treated fibroblasts. Furthermore, ePRP treatment drives the mitochondrial resetting by hindering the mitochondrial biogenesis-related genes and results in a dampened mitochondrial mass. Antioxidant production was further increased by ePRP treatment to prevent reactive oxygen species formation. Besides, ePRP also halts the senescence progression of fibroblasts by activating SIRT1 expression. Importantly, the glycolytic inhibitor 2-DG can completely reverse the ePRP-enhanced wound healing capacity, whereas the mitochondrial inhibitor oligomycin cannot. This is the first study to utilize PRP for comprehensively investigating its effects on the metabolic reprogramming of fibroblasts. These findings indicate that PRP's primary metabolic regulation is to promote metabolic reprogramming toward glycolytic energy metabolism in fibroblasts, preserving redox equilibrium and allowing anabolic pathways necessary for the healing and anti-ageing process.


Assuntos
Glicólise , Plasma Rico em Plaquetas/metabolismo , Pele/citologia , Cicatrização , Técnicas de Cultura de Células , Linhagem Celular , Proliferação de Células , Fibroblastos/citologia , Fibroblastos/metabolismo , Humanos , Medicina Regenerativa , Sirtuína 1/metabolismo , Pele/metabolismo
4.
J Clin Med ; 10(24)2021 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-34945266

RESUMO

Breast cancer-related lymphedema (BCRL) is one of the most significant complications seen after surgery. Several studies demonstrated that extracorporeal shock wave therapy (ESWT), in addition to conventional complex decongestive therapy (CDT), had a positive effect on BCRL in various aspects. The systematic review and meta-analysis aim to explore the effectiveness of ESWT with or without CDT on BRCL patients. We searched PubMed, Embase, PEDro, Cochrane Library Databases, and Google Scholar for eligible articles and used PRISMA2020 for paper selection. Included studies were assessed by the PEDro score, Modified Jadad scale, STROBE assessment, and GRADE framework for the risk of bias evaluation. The primary outcomes were the volume of lymphedema and arm circumference. Secondary outcome measures were skin thickness, shoulder joint range of motion (ROM), and an impact on quality-of-life questionnaire. Studies were meta-analyzed with the mean difference (MD). Eight studies were included in the systemic review and four in the meta-analysis. In summary, we found that adjunctive ESWT may significantly improve the volume of lymphedema (MD = -76.44; 95% CI: -93.21, -59.68; p < 0.00001), skin thickness (MD = -1.65; 95% CI: -3.27, -0.02; p = 0.05), and shoulder ROM (MD = 7.03; 95% CI: 4.42, 9.64; p < 0.00001). The evidence level was very low upon GRADE appraisal. ESWT combined with CDT could significantly improve the volume of lymphedema, skin thickness, and shoulder ROM in patients with BCRL. There is not enough evidence to support the use of ESWT as a replacement for CDT. This study was registered with PROSPERO: CRD42021277110.

5.
Medicine (Baltimore) ; 100(6): e24631, 2021 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-33578580

RESUMO

RATIONALE: The Pisa syndrome (PS) is defined as a kind of reversible postural deformity which causes a lateral trunk flexion of 10 degrees or more. A prevalence of approximately 7.4% to 10.3% of patients with Parkinson disease (PD) also have PS. Though unbalanced function of the basal ganglia network and impaired visual-spatial functions including parietal cortices in PS is known, the pathophysiology of PS remains to be unclear. PATIENT CONCERNS: A 67-year-old male patient with PD visited our Rehabilitation outpatient department because of his trunk which involuntarily deviated to the left side when he stood up. DIAGNOSES: Based on the history, physical examination, X-ray images, Tc-99m brain TRODAT-1 single-photon emission computed tomography (SPECT), and regional cerebral perfusion Tc-99m ethyl cysteinate dimer SPECT, the patient was diagnosed with PD with PS. INTERVENTIONS: The patient refused our recommendation of admission for pharmaceutical treatment due to personal reasons and was only willing to accept physical training programs at our outpatient department. OUTCOMES: We arranged functional neuroimaging of the brain to survey possible neurologic deficits. The patient's images of ethyl cysteinate dimer SPECT and TRODAT SPECT showed abnormalities, including hypoperfusion and diminished dopamine transporter uptake, in the areas of the basal ganglia network and other brain regions. LESSONS: Based on previous literature and the imaging of our patient, we hypothesize that PS results from unbalanced function of the basal ganglia network and impaired visual-spatial functions of bilateral parietal cortices.


Assuntos
Doença de Parkinson/diagnóstico por imagem , Idoso , Humanos , Masculino , Neuroimagem , Compostos de Organotecnécio , Doença de Parkinson/reabilitação , Compostos Radiofarmacêuticos , Síndrome , Tomografia Computadorizada de Emissão de Fóton Único , Tropanos
6.
Clin Appl Thromb Hemost ; 24(9_suppl): 163S-170S, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30213203

RESUMO

Recurrent hemarthrosis in patients with hemophilia (PWH) results in chronic arthropathy requiring total joint replacement (TJR). This study aimed to compare the difference in TJR rate between patients with hemophilia A (HA) and hemophilia B (HB). A final total of 935 PWH (782 HA and 153 HB) without inhibitors were collected from the Taiwan's National Health Insurance Research Database between 1997 and 2013. Demographics, clinical characteristics, and TJR rate were compared between the 2 groups. The annual use of clotting factor concentrate was not different between HA and HB groups (P = .116). The rate of comorbidities except for 29 PWH having HIV who were all in the HA group was also not different between the 2 groups. A total of 99 (10.6%) PWH had undergone 142 TJR procedures during the study period. All of them had received on-demand therapy. No difference was found in the cumulative incidence of TJR between HA and HB (P = .787). After adjusting for various confounders including age, pyogenic arthritis, and HIV infection, no increased risk of TJR was found in patients with HA versus Patients with HB (hazard ratio: 0.92, 95% confidence interval 0.54-1.58). This finding suggests that the rate of TJR between patients with HA and HB is not significantly different.


Assuntos
Artrite , Artroplastia de Substituição , Fatores de Coagulação Sanguínea/administração & dosagem , Bases de Dados Factuais , Hemofilia A , Hemofilia B , Programas Nacionais de Saúde , Adolescente , Adulto , Fatores Etários , Artrite/epidemiologia , Artrite/terapia , Hemofilia A/epidemiologia , Hemofilia A/terapia , Hemofilia B/epidemiologia , Hemofilia B/terapia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Fatores de Risco
7.
J Chin Med Assoc ; 81(10): 926-929, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30017811

RESUMO

Perioperative management of persons with hemophilia (PWH) is a challenge for surgeons and hematologists. Reductions in mortality rate and complications have been achieved since the introduction of clotting factor concentrates (CFCs), which improve hemostatic control. However, there is no clear consensus on the optimal dosing of CFC administration. The aim of this study was to evaluate the outcome of PWH without inhibitors in patients undergoing invasive or surgical procedures. A total of 161 procedures, including 57 major and 104 minor ones were retrospectively reviewed. The characteristics of PWH, age at procedure, duration and total amount of CFC administration during the perioperative period, hemostatic adequacy, and complications were summarized. The study showed a low rate of bleeding (1.2%), infection (0%), thromboembolic event (0%), and inhibitor development (0%). The results revealed the doses and duration of CFC administration for several major and minor procedures which were capable of achieving excellent hemostatic control.


Assuntos
Hemofilia A/complicações , Hemostasia Cirúrgica/métodos , Assistência Perioperatória , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Fatores de Coagulação Sanguínea/uso terapêutico , Criança , Pré-Escolar , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos , Procedimentos Cirúrgicos Operatórios , Tromboembolia/prevenção & controle , Adulto Jovem
8.
BMJ Open ; 8(2): e017442, 2018 02 08.
Artigo em Inglês | MEDLINE | ID: mdl-29439066

RESUMO

OBJECTIVES: It has been proven that statin can protect synovial joints from developing osteoarthritis through its anti-inflammatory effects. However, studies on the effect of statins on spinal degenerative joint diseases are few and limited to in vitro studies. Therefore, we investigated the relationship between the statin dosage and the development of spinal degenerative joint diseases. DESIGN: A retrospective cohort study. SETTING: Patients registered in Taiwan National Health Insurance Research Database. PARTICIPANTS: Patients aged 40-65 years old from 2001 to 2010 were included. Those who received statin treatment before 2001, were diagnosed with spinal degenerative joint diseases or received any spinal surgery before 2004 or had any spinal trauma before 2011 were excluded. A total of 7238 statin users and 164 454 non-users were identified and followed up for the next 7 years to trace the development of spinal degenerative joint disease. OUTCOME MEASURES: The incident rate of spinal degenerative joint diseases and HRs among the groups treated with different statin dosages. RESULTS: A higher dosage of statins was associated with a significantly lower risk of developing spinal degenerative joint disease in patients with hypercholesterolaemia. Compared with the group receiving less than 5400 mg of a statin, the HR of the 11 900-28 000 mg group was 0.83 (95% CI 0.70 to 0.99), and that of the group receiving more than 28 000 mg was 0.81 (95% CI 0.68 to 0.97). Results of subgroup analysis showed a significantly lower risk in men, those aged 50-59 years and those with a monthly income less than US$600. CONCLUSIONS: Our study's findings clearly indicated that a higher dosage of statins can reduce the incidence of spinal degenerative joint disease in patients with hypercholesterolaemia, and it can be beneficial for people with a higher risk of spine degeneration.


Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Hiperlipidemias/complicações , Dor Lombar/fisiopatologia , Osteoartrite da Coluna Vertebral/epidemiologia , Osteoartrite da Coluna Vertebral/prevenção & controle , Adulto , Distribuição por Idade , Idoso , Comorbidade , Feminino , Seguimentos , Humanos , Incidência , Renda/estatística & dados numéricos , Estimativa de Kaplan-Meier , Dor Lombar/epidemiologia , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Medição de Risco , Distribuição por Sexo , Taiwan/epidemiologia
9.
Oncotarget ; 7(24): 35522-35534, 2016 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-27203679

RESUMO

Benign paroxysmal positional vertigo (BPPV) is one of the most common complaints encountered in clinics and is strongly correlated with advanced age or, possibly, degeneration. Redistribution exercises are the most effective approaches to treat BPPV, and canalith repositioning procedure (CRP) cure most BPPV cases. However, the mechanisms through which the treatment modulates systemic molecules in BPPV patients remain largely unknown. In this study, we report that the miR-34a and Sirtuin 1 (SIRT1) genes correlated with the treatment effects of CRP in BPPV subjects. We found that miR-34a expression was largely inhibited and SIRT1 expression was significantly reversed after BPPV maneuver treatment. We also confirmed that the PPAR-γ, PGC-1 and FoxO gene expressions were decreased immediately after canalith repositioning procedure (CRP) for BPPV, and were largely increased after a complete cure of BPPV. Moreover, we observed that after a complete recovery of BPPV, the ROS concentrations, pro-inflammatory cytokine concentrations and p53 expression levels were attenuated. We conclude that BPPV treatment might involve some epigenetic regulations through the mediation of miR-34a, SIRT1 functions and repression of redox status.


Assuntos
Vertigem Posicional Paroxística Benigna/genética , Vertigem Posicional Paroxística Benigna/terapia , Epigênese Genética , Regulação da Expressão Gênica , MicroRNAs/metabolismo , Sirtuína 1/metabolismo , Fatores Etários , Idoso , Vertigem Posicional Paroxística Benigna/sangue , Citocinas/metabolismo , Terapia por Exercício , Proteína Forkhead Box O1/metabolismo , Humanos , MicroRNAs/sangue , Pessoa de Meia-Idade , Membrana dos Otólitos/fisiopatologia , PPAR gama/metabolismo , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Canais Semicirculares/fisiopatologia , Resultado do Tratamento , Proteína Supressora de Tumor p53/metabolismo
10.
Neurobiol Aging ; 36(9): 2607-16, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26130063

RESUMO

Benign paroxysmal positional vertigo (BPPV) is one of the most frequently encountered primary complaints in dizziness clinics. The incidence of BPPV has been proven to increase with age. The relationship between BPPV and another neurodegenerative disease, Parkinson's disease (PD), has not been previously discussed. This study aimed to investigate the relationship of BPPV and PD with oxidative stress. A total of 30,811 subjects participated in our cohort study. The study cohort comprised 5057 BPPV patients and a comparison cohort of 25,754 nonBPPV patients. SIRT1 axis gene expression was investigated in BPPV patient blood samples and a PD cell model of 6-hydroxydopamine (6-OHDA)-treated PC-12 cells to elucidate the potential in vitro and in vivo mechanisms of degeneration in PD and BPPV. Our data suggest that BPPV patients with histories of head injuries show a significantly higher hazard to develop subsequent PD (hazard ratio, 3.942; confidence interval, 1.523-10.205, p = 0.005). We also observed that oxidative status is increased in blood samples from patients with BPPV. Our in vitro study suggests that SIRT1 function is inhibited by oxidative stress, which thereby promotes 6-hydroxydopamine-induced cell death. We conclude that BPPV is independently associated with an increased risk of PD. This finding may be attributed to oxidative stress-mediated inhibition of SIRT1 expression levels.


Assuntos
Vertigem Posicional Paroxística Benigna/sangue , Vertigem Posicional Paroxística Benigna/epidemiologia , Estresse Oxidativo/genética , Doença de Parkinson/epidemiologia , Sirtuína 1/sangue , Adrenérgicos/farmacologia , Adulto , Fatores Etários , Idoso , Animais , Cromonas/farmacologia , Estudos de Coortes , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Masculino , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Pessoa de Meia-Idade , Fator de Crescimento Neural/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Oxidopamina/farmacologia , Células PC12/efeitos dos fármacos , Doença de Parkinson/sangue , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Ratos , Espécies Reativas de Oxigênio/metabolismo , Sirtuína 1/genética , Superóxido Dismutase/sangue , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Proteína X Associada a bcl-2/metabolismo
11.
J Biochem ; 158(4): 299-308, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25922201

RESUMO

Low back pain is a common clinical problem that causes disability and impaired quality of life. While the reason behind low back pain was largely considered to be of musculoskeletal origin, the contribution of inflammatory cytokines and oxidative stress could never be overlooked. Exercise has been proven to be an effective approach to treat low back pain. However, the mechanism of the exercise effect on the inflammatory cytokines and oxidative stress is still largely unknown. In this study, we revealed that exercise intervention reduces Toll-like receptor 4 (TLR-4) pathway and enhances Sirtuin 1 (SIRT1) expression in low back pain patients. We also confirmed that exercise up-regulates the expression of peroxisome proliferator-activated receptor-gamma, PPAR-γ coactivator-1 and FoxOs family proteins and also increases the activity of catalase and superoxide dismutase in patients with low back pain. Furthermore, we found that exercise intervention attenuates the oxidative stress, pro-inflammatory cytokine concentrations and p53 expression in patients with low back pain. This study demonstrates that exercise intervention improves low back pain symptoms through regulation of the SIRT1 axis with repression of oxidative stress and TLR-4 inhibition.


Assuntos
Regulação da Expressão Gênica , Dor Lombar/terapia , Exercícios de Alongamento Muscular , Estresse Oxidativo , Treinamento Resistido , Sirtuína 1/metabolismo , Receptor 4 Toll-Like/metabolismo , Adulto , Estudos Transversais , Citocinas/sangue , Citocinas/metabolismo , Feminino , Proteína Forkhead Box O1 , Proteína Forkhead Box O3 , Fatores de Transcrição Forkhead/genética , Fatores de Transcrição Forkhead/metabolismo , Humanos , Dor Lombar/sangue , Dor Lombar/imunologia , Dor Lombar/metabolismo , Linfócitos/imunologia , Linfócitos/metabolismo , Masculino , Pessoa de Meia-Idade , PPAR gama/genética , PPAR gama/metabolismo , Medição da Dor , Sirtuína 1/genética , Taiwan , Receptor 4 Toll-Like/genética
12.
J Stroke Cerebrovasc Dis ; 24(6): 1317-23, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25891753

RESUMO

BACKGROUND: The goal of the study was to compare the effects of isokinetic and isotonic strengthening program on the changes of muscle strength, functional capacity, life quality, and inflammatory cytokines in hemiparetic patients within 6 months of stroke attack. METHODS: Thirty-one participants were randomly assigned into either isotonic training group or isokinetic training group. Both training programs were carried out 5 days a week for a total of 4 weeks. Outcome measures included the peak isometric torque of knees at 90° flexion, the peak torque of knees extension and flexion at angular velocities 60°/s and 120°/s, Short Form 36 (SF-36) Health Survey Questionnaire, Timed Up and Go test, and inflammatory cytokines including high sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor-α. RESULTS: Seven patients were not able to complete the training program and were excluded from our study. The results from the remaining 24 patients showed that there were more peak torque, and SF-36 items significantly improved in the isokinetic training group compared with the isotonic group. The Timed Up and Go test and interleukin-6 were improved in both groups, but tumor necrosis factor-α was improved in only the isokinetic group. There were no significant differences between the improvements of the 2 groups except the isokinetic flexion torque at 60°/s and 120°/s. CONCLUSIONS: Early strengthening exercise is important for subacute stroke patients, and isokinetic program, if accessible, can bring more significant benefits for them.


Assuntos
Força Muscular/fisiologia , Treinamento Resistido/métodos , Reabilitação do Acidente Vascular Cerebral , Idoso , Proteína C-Reativa/metabolismo , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/fisiopatologia , Resultado do Tratamento , Fator de Necrose Tumoral alfa/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA